Recommended

Sarepta’s DMD drug Elevidys issued FDA label update
Rare disease gene therapy granted European first approval
Johnson & Johnson agrees $3bn oncology acquisition
European Commission grants EU first for J&J’s Simponi biosimilar
Researchers validate approach that supports animal-based pyrogen test replacement
ON DEMAND webinar: automating QC testing for radiopharmaceutical production
Insmed secures EU approval for Brinsupri (brensocatib)
Moderna invests over $140m to onshore mRNA medicine manufacturing in US

List view / Grid view

News

NICE recommends secukinumab for people with ankylosing spondylitis

4 August 2016 | By National Institute for Health and Care Excellence (NICE)

The National Institute for Health and Care Excellence (NICE) has recommended innovative new drug secukinumab for treating ankylosing spondylitis, a type of arthritis that mainly affects the back....

ReNeuron Group publishes stroke clinical data

4 August 2016 | By Niamh Louise Marriott, Digital Content Producer

The PISCES I study was the first clinical trial of ReNeuron’s CTX cell therapy candidate for patients with motor disability as a consequence of ischaemic stroke. The data, collated over two years relates to the eleven stroke patients treated in the study...

Atrial fibrillation market will peak in 2022 before decline to $4.9 Billion by 2025, says GlobalData
Atrial fibrillation market will peak in 2022 before decline to $4.9 Billion by 2025, says GlobalData

Atrial fibrillation market will peak at $11.8 billion in 2022

2 August 2016 | By GlobalData

The atrial fibrillation market will expand from approximately $8 billion in 2015 to hit its peak of $11.8 billion in 2022, after which the impact of patent expiries will see the market value fall rapidly to $4.9 billion by 2025, according to research and consulting firm GlobalData...

Biopotency signals demonstrated in Sanfilippo type A Gene therapy trial, provides Abeona Therapeutics
Biopotency signals demonstrated in Sanfilippo type A Gene therapy trial, provides Abeona Therapeutics

Sanfilippo type A Gene therapy trial shows biopotency signals, provides Abeona Therapeutics

2 August 2016 | By Abeona Therapeutics Inc

Abeona Therapeutics provides an update on its first Sanfilippo patient and reports that early biopotency signals suggest a reduction of heparan sulfate in the urine of patients and if confirmed will suggest that intravenous administration of ABO-102 may ultimately provide both central nervous system and systemic benefits to patients...

PharmaMar initiates a phase III ATLANTIS study in patients with small cell lung cancer
PharmaMar initiates a phase III ATLANTIS study in patients with small cell lung cancer

PharmaMar initiates a phase III ATLANTIS study for small cell lung cancer

2 August 2016 | By PharmaMar

PharmaMar announced the start of a pivotal Phase III ATLANTIS study evaluating efficacy and safety of PM1183 (lurbinectedin) in combination with doxorubicin versus topotecan or the combination VCR (cyclophosphamide, adriamicine (doxorubicin) and vincristine) in patients with small cell lung cancer after the failure of one prior platinum-containing line.

cimzia arthritis x-ray hands bones
cimzia arthritis x-ray hands bones

Sanofi and Regeneron announce EMA acceptance for review of Marketing Authorisation Application for sarilumab

1 August 2016 | By Sanofi / Regeneron Pharmaceuticals, Inc.

Sanofi and Regeneron Pharmaceuticals, Inc. have announced that the European Medicines Agency has accepted for review the Marketing Authorisation Application for sarilumab, an investigational human monoclonal antibody directed against the IL-6 receptor that is intended for the treatment of adult patients with moderately to severely active rheumatoid arthritis...

FDA grants fast track for Shire’s NASH investigational treatment
FDA grants fast track for Shire’s NASH investigational treatment

FDA grants fast track for Shire’s NASH investigational treatment

29 July 2016 | By Mandy Parrett, Editorial Assistant

Shire Plc has announced today that the United States Food and Drug Administration (FDA) has granted Fast Track designation for SHP626 (volixibat) for an investigational treatment of adults with nonalcoholic steatohepatitis (NASH) with liver fibrosis.